SLC5A2 and hydrops fetalis: Notably, SGLT-2 inhibitors, which now have indications for HF treatment, have been reported to reduce SBP in HFpEF patients while demonstrating cardiovascular benefits (primarily through reduced HF hospitalizations) [41].